scholarly journals Topical antibiotics for acute rhinosinusitis in children

2021 ◽  
pp. 64-71
Author(s):  
E. P. Karpova ◽  
D. A. Tulupov ◽  
V. A. Grabovskaya
Keyword(s):  
Antibiotic Therapy ◽  
Nasal Cavity ◽  
Chronic Rhinosinusitis ◽  
Inhalation Therapy ◽  
Nasal Discharge ◽  
Antibacterial Drugs ◽  
Systemic Antibiotic ◽  
Acute Rhinosinusitis ◽  
Nasal Symptoms ◽  
Systemic Antibiotic Therapy

The authors presented an overview of the existing data on inhalation therapy with antibacterial drugs in acute rhinosinusitis and exacerbation of chronic rhinosinusitis in children. The overview includes general information about the etiology and features of the course of acute rhinosinusitis. It also contains indications for systemic and topical antibiotic therapy in acute rhinosinusitis specified in the Russian clinical guidelines. The advantages of using a combination preparation of thiampheni-col and N-acetylcysteine by inhalation therapy for acute rhinosinusitis in children and adults are considered separately. A clinical case of a 15-year-old female patient with complaints of persistent rhinitis over the past 4-5 years is discussed. Historical information: a patient had a runny nose over the last 4-5 years: persistent, viscous nasal discharge with moderate nasal congestion. Nasal symptoms worsened with episodes of acute respiratory illness, and nasal discharge became mucopurulent. The child was preliminarily diagnosed with chronic rhinosinusitis (incomplete remission), moderate course. To reduce the severity of the symptoms of the disease, which were present at the time of examination, the following were recommended: daily one-to-two irrigation of the nasal cavity with slightly hypertonic (1.5-3%) solutions of sea water, followed by a toilet of the nasal cavity; in case of episodes of colds with the appearance of mucopurulent secretions, inhalation therapy in a pulsating mode of the inhaler with a solution of thiamphenicol and N-acetylcysteine at a dose of 500 mg once a day (in the first half of the day) for the next 10 days and further; the use of a nasal spray of mometasone furoate, 200 mcg per day during inhalation therapy for another 3 weeks. At the follow-up examination after 10 days of treatment, the patient reported a significant decrease in the severity of nasal symptoms, which coincided with an improvement in the rhinoscopic status. It can be concluded that the use of topical antibacterial drugs by inhalation therapy for acute rhinosinusitis, despite all its advantages, is not an equivalent substitute for systemic antibiotic therapy in the treatment of severe and especially complicated forms of the disease. The inhalation therapy is recommended in the presence of indications for systemic antibiotic therapy, since it is an auxiliary method of treatment, the action of which is aimed at enhancing the effect of systemic antibiotics.

scholarly journals The inhalation antibioticotherapy of acute bacterial rhinosinusitis

2018 ◽  
pp. 50-54 ◽  
Author(s):  
I. B. Angotoeva ◽  
D. S. Pshennikov
Keyword(s):  
Antibiotic Therapy ◽  
Nasal Cavity ◽  
Paranasal Sinuses ◽  
Hospital Admissions ◽  
Treatment Options ◽  
Nasal Endoscopy ◽  
Inhalation Therapy ◽  
Systemic Antibiotic Therapy ◽  
Acute Bacterial Rhinosinusitis ◽  
Active Anterior Rhinomanometry

Epidemiological studies conducted throughout the world show that the inflammatory diseases of the nasal cavity and paranasal sinuses are the leading cause of otorhinolaryngology (ENT) hospital admissions and outpatient clinic referral. Although the most common cause of acute rhinosinusitis is viral infection, antibiotics are prescribed in more than 80% of cases, which may lead to the development of antimicrobial resistance. The topical inhalation therapy with the inhalation Complex «PARI SINUS device» (сompressor and nebulizer) may provide better treatment options for patients who suffer from the diseases of the nasal cavity and paranasal sinuses. Purpose of the study is to evaluate the efficacy of topical inhalation treatment of acute bacterial rhinosinusitis using pulsating aerosol in comparison with systemic antibiotic therapy. Materials and methods. 60 adult patients at the age from 19 to 62 years with the diagnosis uncomplicated moderate acute bacterial rhinosinusitis has been included in opened randomized controlled trial. 30 patients have been with the inhalation therapy by the combined drug Fluimucil® antibiotic IT (thiamphenicol glycinate acetylcystein, Zambon) using PARI SINUS device during 7 days. Controls – 30 patients have been treated with antibiotic therapy of acute bacterial rhinosinusitis using 875/125 mg oral amoxicillin/clavulanate twice daily for 7 days. The result was evaluated by the dynamics of the symptoms of acute bacterial rhinosinusitis (nasal congestion, blockage, facial pain and reduction of smell), active anterior rhinomanometry and nasal endoscopy. Results. For main symptoms of acute bacterial rhinosinusitis was no significant benefit of antibiotic therapy as compared to topical inhalation therapy using pulsating aerosol. Both treatment options were effective against acute bacterial rhinosinusitis, which is confirmed by the improvement of symptoms, active anterior rhinomanometry and nasal endoscopy. Conclusion. The topical nebulizer therapy of acute bacterial rhinosinusitis may provide better treatment options, because systemic antibiotics can be associated with different adverse effects.

scholarly journals Systemic antibiotic therapy as an adjunct to non‐surgical peri‐implantitis treatment: A single‐blind RCT

2021 ◽  
Author(s):  
Yvonne C. M. De Waal ◽  
Tine E. Vangsted ◽  
Arie Jan Van Winkelhoff
Keyword(s):  
Antibiotic Therapy ◽  
Systemic Antibiotic ◽  
Systemic Antibiotic Therapy ◽  
Single Blind

Delayed tooth replantation in rats: effect of systemic antibiotic therapy with amoxicillin and tetracycline

2015 ◽  
Vol 31 (6) ◽  
pp. 448-456 ◽  
Author(s):  
Weglis Dyanne de Souza Gomes ◽  
Cristina Antoniali Silva ◽  
Moriel Evangelista Melo ◽  
Vanessa Ferreira da Silva ◽  
Melyna Marques de Almeida ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Systemic Antibiotic ◽  
Tooth Replantation ◽  
Systemic Antibiotic Therapy

Abscesses of the breast: US-guided serial percutaneous aspiration and local antibiotic therapy after unsuccessful systemic antibiotic therapy

2001 ◽  
Vol 42 (2) ◽  
pp. 161-165 ◽  
Author(s):  
A. Imperiale ◽  
F. Zandrino ◽  
M. Calabrese ◽  
G. Parodi ◽  
T. Massa
Keyword(s):  
Antibiotic Therapy ◽  
Percutaneous Aspiration ◽  
Systemic Antibiotic ◽  
Systemic Antibiotic Therapy ◽  
Local Antibiotic ◽  
Local Antibiotic Therapy

Systemic antibiotic therapy in periodontics

1996 ◽  
Vol 10 (1) ◽  
pp. 45-78 ◽  
Author(s):  
Arie Jan Van Winkelhoff ◽  
Thomas E. Rams ◽  
Jørgen Slots
Keyword(s):  
Antibiotic Therapy ◽  
Systemic Antibiotic ◽  
Systemic Antibiotic Therapy

Timing Affects the Clinical Outcome of Adjunctive Systemic Antibiotic Therapy for Generalized Aggressive Periodontitis

2007 ◽  
Vol 78 (7) ◽  
pp. 1201-1208 ◽  
Author(s):  
Doğan Kaner ◽  
Claudia Christan ◽  
Thomas Dietrich ◽  
Jean-Pierre Bernimoulin ◽  
Bernd-Michael Kleber ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Antibiotic Therapy ◽  
Aggressive Periodontitis ◽  
Systemic Antibiotic ◽  
Systemic Antibiotic Therapy

Current antibiotic therapy of endo-perio lesions with secondary endodontic involvement

2021 ◽  
Vol 26 (2) ◽  
pp. 105-113
Author(s):  
L. Yu. Orekhova ◽  
V. G. Atrushkevitch ◽  
E. S. Loboda ◽  
V. Yu. Vashneva ◽  
A. A. Petrov
Keyword(s):  
Antibiotic Therapy ◽  
Antibiotic Sensitivity ◽  
Endodontic Treatment ◽  
Comprehensive Treatment ◽  
Sensitivity Testing ◽  
Microbiological Test ◽  
Systemic Antibiotic ◽  
Periodontal Inflammation ◽  
Systemic Antibiotic Therapy ◽  
Group 2

Relevance. Successful treatment of endo-perio lesions depends on the thorough clinical assessment, accurate diagnosis and structural approach to the planning of periodontal and endodontic treatment. Aim – to provide clinical and laboratory evidence about the effectiveness of ciprofloxacin-and-tinidazole-containing antibiotic in the comprehensive treatment of endo-perio lesions with a primary periodontal disease which secondarily affects the pulp.Materials and methods. We examined 29 patients aged from 35 to 50 (mean age 42.3±3.21) with class II endo-perio lesions according to P. Eickholz classification. The patients were randomly divided into 2 groups. All patients had comprehensive periodontal and endodontic treatment with (Group 2) and without (Group 1) antibiotic therapy. The clinical and paraclinical examination included determination of such indices as OHI-s, SL, PMA, SBI, as well as Doppler ultrasound, EPT, CBCT, microbiological test of the discharge from periodontal pockets and root canal system. We selected the systemic antibiotic after the antibiotic sensitivity testing.Results. Comprehensive treatment of endo-perio lesions, which included systemic antibiotic therapy with ciprofloxacin and tinidazole, effectively arrested the inflammation in the periodontium and pulp beginning from the 7th day of use.Conclusion. Cifran ST, a combination broad-spectrum antibiotic, helps reduce periodontal inflammation by effectively eliminating microbiota in the root canals and periodontal pockets in patients with moderate or severe chronic generalized periodontitis. 

scholarly journals Use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)® for the Control of Recurrent Pyoderma Eczema in Dogs with Atopic Dermatitis

2018 ◽  
Vol 44 (1) ◽  
pp. 7 ◽  
Author(s):  
Suzana Evelyn Bahr Solomon ◽  
Marconi Rodrigues de Farias ◽  
Claudia Turra Pimpão
Keyword(s):  
Staphylococcus Aureus ◽  
Atopic Dermatitis ◽  
Antibiotic Therapy ◽  
Significant Decline ◽  
Microbiological Analysis ◽  
Phage Lysate ◽  
Systemic Antibiotic ◽  
Therapeutic Protocol ◽  
Systemic Antibiotic Therapy ◽  
The Mean

Background: Recurrent staphylococcal infections are frequent in dogs with atopic dermatitis (AD). Many factors seem to contribute to making bacterial pyoderma refractory to treatment. Short-term systemic antibiotic therapy is effective for the treatment of acute symptoms, and may, along with pulsatile therapy, contribute to the long-term control of the disease. However, microbial resistance has become a growing and alarming problem. The aim of this study was to evaluate whether the use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)®, can minimize the symptoms of recurrent pyoderma and increase the interval between acute atopic manifestations in dogs.Materials, Methods & Results: Thirteen dogs with a history of Canine Atopic Dematitis (CAD) and recurrent bacterial pyoderma received SPL at increasing intervals for 23 weeks. The contents of an intact pustule of each dog was collected and submitted to microbiological analysis. Systemic antibiotic therapy was established for the first 4-6 weeks of SPL protocol, based on the antibiotic sensitivity tests. The animals included in the study underwent a therapeutic protocol receiving shots of 0.5 mL of SPL subcutaneously (SC) twice a week for the first 12 weeks; 1.0 mL of SPL (SC) once a week for four weeks; 1.0 mL of SPL (SC) once every 15 days; 1.0 mL of SPL (SC) after a three-week interval from the last dose on week 20, until final observation at week 26, with no application. The animals underwent clinical examination every week and the evaluation of pruritus was used according Rybnicek et al. During the therapeutic protocol with SPL, a significant decline in the pruritus was observed in the treated dogs (P < 0.05). In week 1, the mean pruritus index was 7.33 on the Rybnicek scale; in weeks 12 and 23, the mean indices were 2.41 and 1.91. An effectiveness of 83.33% for the control of pruritus along with regression of the lesions was observed.Discussion: Before treatment, the selected animals presented worsening of the pruritus during the pyoderma eczema episodes (pruritic), resulting in the emergence of a vicious cycle where the pruritus induced the appearance of new lesions, requiring the use of antibiotics for a long period. During the therapeutic protocol with SPL, a significant decline in the pruritus was observed in the treated dogs. The control of pruritus associated with pyoderma eczema of the dogs in this study before the vaccination protocol with SPL was satisfactory when they were subjected to antibiotic therapy; however, after suspending therapy, the bacterial infections recurred, on average, after 2-4 weeks. On the other hand, with the use of SPL, the animals were recurrence-free until the end of the experimental protocol. This was attributed to the antibiotic therapy administered at the beginning of the protocol, as this led to a regression of the bacterial pyoderma and involution of the lesions. However, after suspending antibiotics, it was observed that, by the end of the study, 83.33% of the dogs still had a low level of pruritus, few or no lesions, which were considered acceptable to most owners. At this moment none of these patients needed to be subjected to antibiotic treatment. The sums of the scores for the dogs on weeks 1, 12, and 23 were 53.33, 4.41, and 3.5, respectively, indicating significant improvements of the lesions, showing that the proposed protocol with SPL was able to prevent new episodes of pyoderma.

scholarly journals Non-infectious causes of chronic pharyngitis

2018 ◽  
pp. 112-115
Author(s):  
S. Ya. Kosyakov ◽  
I. B. Angotoeva ◽  
A. N. Isamov
Keyword(s):  
Antibiotic Therapy ◽  
Sore Throat ◽  
Inflammatory Process ◽  
Common Disease ◽  
Main Symptom ◽  
Systemic Antibiotic ◽  
Pharyngeal Mucosa ◽  
Systemic Antibiotic Therapy

Chronic pharyngitis (CP) is a common disease that is not associated with infections and does not require administration of any systemic antibiotic therapy. Many non-infectious factors cause CP. Despite diversity and variability of factors, the inflammatory process of the pharyngeal mucosa lie at the root of the pathogenesis of CP. A sore throat is the main symptom of this process, which can be successfully relieved with local drugs.

scholarly journals Inhaled antibiotics to improve efficacy and safety in the treatment of upper airway and lung inflammatory diseases

2021 ◽  
pp. 84-92
Author(s):  
Vladimir N. Drozdov ◽  
Konstantin I. Arefev ◽  
Svetlana Y. Serebrova ◽  
Irina A. Komissarenko ◽  
Evgenia V. Shikh ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Targeted Delivery ◽  
Whooping Cough ◽  
Inflammatory Diseases ◽  
Wide Spectrum ◽  
Chronic Obstructive ◽  
Combination Drug ◽  
Antibacterial Drugs ◽  
Systemic Antibiotic Therapy ◽  
Inhaled Antibiotics

Inhaled antibacterial drugs have been used since the 1940s with greater or lesser effectiveness, due to the possibility of targeted delivery of drugs directly to the infection site at concentrations higher than MICs. High local concentrations of antibacterial agents expand the possibilities of treating infections caused by multiresistant strains and reduces antibiotic resistance in the population. The inhaled delivery method is characterized by a high level of safety due to the absence of systemic toxic effects, which reduces the risk of pseudomembranous colitis and other complications of antibiotic therapy. Thiamphenicol glycinate acetylcysteinate is a combined drug that includes thiamphenicol and N-acetylcysteine, which causes its antibacterial and mucolytic activity. The results of clinical studies have demonstrated the effectiveness of TGA in the treatment of acute and chronic bronchitis, chronic obstructive pulmonary disease, community-acquired pneumonia, laryngotracheitis, rhinosinusitis and other infections of the upper and lower respiratory tract. In pediatrics, the drug is used to treat bronchitis and pneumonia, especially those that cannot be treated with other antibacterial drugs, bronchiolitis, whooping cough, and cystic fibrosis. The article presents data on the effectiveness and safety of containing TGA. A wide spectrum of antibacterial actions, the ability to form high local concentrations of antibacterial and mucolytic components in the focus of infection, a low risk of serious side effects in both adults and children are noted. The topical use of the combination drug has proven to be effective not only in bringing about a pronounced clinical improvement, but also in reducing the frequency of use of systemic antibiotic therapy. The efficacy of thiamphenicol glycinate acetylcysteinate is not inferior to macrolide antibiotics.

Sign in / Sign up

Export Citation Format

Share Document